CA1335289C
(en)
*
|
1987-10-26 |
1995-04-18 |
Fujio Antoku |
Piperidinyl benzisoxazole derivatives, their production and pharmaceutical use
|
US5116970A
(en)
*
|
1988-02-18 |
1992-05-26 |
New James S |
Psychotropic heterobicycloalkylpiperazine derivatives: 2. fused pyridazinones
|
US5001130A
(en)
*
|
1988-02-18 |
1991-03-19 |
Bristol-Myers Company |
Psychotropic heterobicycloalkylpiperazine derivatives
|
GR1000667B
(el)
*
|
1988-03-21 |
1992-09-25 |
Janssen Pharmaceutica Nv |
Μεθοδος παρασκευης 3-πιπεριδινυλο-1,2-βενζισοξαζολων.
|
US4957916A
(en)
*
|
1988-08-05 |
1990-09-18 |
Janssen Pharmaceutica N.V. |
Antipsychotic 3-piperazinylbenzazole derivatives
|
NZ230045A
(en)
*
|
1988-08-05 |
1990-11-27 |
Janssen Pharmaceutica Nv |
3-piperazinylbenzazole derivatives and pharmaceutical compositions
|
US5015740A
(en)
*
|
1988-08-05 |
1991-05-14 |
Janssen Pharmaceutica N.V. |
Antipsychotic 3-piperazinylbenzazole derivatives
|
US5321028A
(en)
*
|
1988-09-02 |
1994-06-14 |
Janssen Pharmaceutica N.V. |
Antihypertensive 3-piperidinyl-indazole derivatives
|
IL90879A0
(en)
*
|
1988-09-02 |
1990-02-09 |
Janssen Pharmaceutica Nv |
3-piperidinyl-indazole derivatives,their preparation and antihypertensive compositions containing them
|
US5196425A
(en)
*
|
1988-09-02 |
1993-03-23 |
Janssen Pharmaceutica N.V. |
Antihypertensive 3-piperidinyl-indazole derivatives
|
US5158952A
(en)
*
|
1988-11-07 |
1992-10-27 |
Janssen Pharmaceutica N.V. |
3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
|
CA2000786C
(en)
*
|
1988-11-07 |
1999-01-26 |
Cornelus G. M. Janssen |
3-piperidinyl-1,2-benzisoxazoles
|
US5254556A
(en)
*
|
1988-11-07 |
1993-10-19 |
Janssen Pharmaceutica N.V. |
3-piperidinyl-1,2-benzisoxazoles
|
WO1990006303A1
(en)
*
|
1988-12-02 |
1990-06-14 |
Pfizer Inc. |
Arylpiperidine derivatives
|
FR2641278B1
(fr)
*
|
1989-01-05 |
1991-03-22 |
Lipha |
Piperidines, procedes de preparation et medicaments les contenant
|
US5256659A
(en)
*
|
1989-01-09 |
1993-10-26 |
Janssen Pharmaceutica N.V. |
2-aminopyrimidinone derivatives
|
GB8900382D0
(en)
*
|
1989-01-09 |
1989-03-08 |
Janssen Pharmaceutica Nv |
2-aminopyrimidinone derivatives
|
FR2654104B1
(fr)
*
|
1989-11-07 |
1992-01-03 |
Adir |
Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
|
FR2671350A1
(fr)
*
|
1991-01-08 |
1992-07-10 |
Adir |
Nouveaux derives de benzisoxazole et de benzisothiazole, leur procede de preparation, et les compositions pharmaceutiques les renfermant.
|
GB9008850D0
(en)
*
|
1990-04-19 |
1990-06-13 |
Janssen Pharmaceutica Nv |
Novel 2,9-disubstituted-4h-pyridol(1,2-a)pyrimidin-4-ones
|
US5075315A
(en)
*
|
1990-05-17 |
1991-12-24 |
Mcneilab, Inc. |
Antipsychotic hexahydro-2H-indeno[1,2-c]pyridine derivatives
|
AU652759B2
(en)
*
|
1990-06-01 |
1994-09-08 |
Aventisub Ii Inc. |
(+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)- 4-piperidinemethanol
|
US6004980A
(en)
*
|
1990-06-01 |
1999-12-21 |
Merrell Pharmaceuticals, Inc. |
(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
|
US5147881A
(en)
*
|
1990-11-14 |
1992-09-15 |
Pfizer Inc |
4-(1,2-benzisoxazolyl)piperidine antipsychotic agents
|
EP0602242A4
(en)
*
|
1991-08-22 |
1994-06-29 |
Yoshitomi Pharmaceutical |
Benzisoxazole compound and use thereof.
|
CA2118936A1
(en)
*
|
1991-09-25 |
1993-04-01 |
Gene M. Bright |
Neuroleptic 2-substituted perhydro-1-h-pyrido[1,2-a]pyrazines
|
US5532243A
(en)
*
|
1992-02-14 |
1996-07-02 |
The Dupont Merck Pharmaceutical Company |
Antipsychotic nitrogen-containing bicyclic compounds
|
DE4243287A1
(de)
*
|
1992-06-19 |
1993-12-23 |
Basf Ag |
N-Substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung
|
NZ254113A
(en)
|
1992-07-13 |
1995-08-28 |
Janssen Pharmaceutica Nv |
Fused piperidine derivatives and medicaments
|
TW376319B
(en)
*
|
1993-04-28 |
1999-12-11 |
Janssen Pharmaceutica Nv |
Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
|
DE4338396A1
(de)
*
|
1993-11-10 |
1995-05-11 |
Basf Ag |
N-Substituierte Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
|
ES2236700T3
(es)
*
|
1993-11-19 |
2005-07-16 |
Janssen Pharmaceutica N.V. |
1,2-benzazoles microencapsulados.
|
EP0730594B1
(en)
*
|
1993-11-23 |
1999-09-08 |
Janssen Pharmaceutica N.V. |
9-HYDROXY-PYRIDO [1,2-a]PYRIMIDIN-4-ONE ETHER DERIVATIVES
|
ES2074966B1
(es)
*
|
1994-02-11 |
1996-06-16 |
Vita Invest Sa |
Procedimiento para la obtencion de 3-(2-(4-(6-fluoro-benzo(d)isoxazol-3-il)piperidin-1-il)-etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido-(1,2-a)pirimidin-4-ona.
|
ES2085234B1
(es)
*
|
1994-02-24 |
1997-01-16 |
Vita Invest Sa |
Agente activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
|
CA2144669A1
(en)
*
|
1994-03-29 |
1995-09-30 |
Kozo Akasaka |
Biphenyl derivatives
|
EP0794185A4
(en)
*
|
1994-11-25 |
1998-03-25 |
Meiji Seika Co |
BICYCLIC THIAZOLE COMPOUND
|
JP3274579B2
(ja)
*
|
1995-01-12 |
2002-04-15 |
住友製薬株式会社 |
脳血管障害に伴う精神症候治療剤
|
TR199700873T1
(xx)
|
1995-02-28 |
1998-01-21 |
H. Lund-Beck A/S |
4-Aminotetrahidrobenzizoksazol veya -izotiazol bile�ikleri.
|
TW592729B
(en)
*
|
1995-04-06 |
2004-06-21 |
Janssen Pharmaceutica Nv |
Rate-controlled transdermal administration of risperidone
|
KR960042947A
(ko)
*
|
1995-05-09 |
1996-12-21 |
김주용 |
고집적 반도체 소자 및 그 국부 연결 방법
|
ES2097093B1
(es)
*
|
1995-05-26 |
1998-01-16 |
Ferrer Int |
Nuevos compuestos derivados de 5h-tiazolo (3,2-a) pirimidin-5-ona.
|
US6028083A
(en)
*
|
1997-07-25 |
2000-02-22 |
Hoechst Marion Roussel, Inc. |
Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
|
UA72189C2
(uk)
*
|
1997-11-17 |
2005-02-15 |
Янссен Фармацевтика Н.В. |
Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
|
ES2141671B1
(es)
*
|
1997-12-26 |
2001-01-01 |
Vita Invest Sa |
Compuesto pirimidinico activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
|
FR2802101B1
(fr)
|
1999-12-10 |
2003-02-28 |
Aventis Pharma Sa |
Association de cymemazine et d'un neuroleptique atypique
|
US6770478B2
(en)
*
|
2000-02-10 |
2004-08-03 |
The Regents Of The University Of California |
Erythrocytic cells and method for preserving cells
|
CZ295402B6
(cs)
*
|
2000-05-05 |
2005-08-17 |
Rpg Life Sciences Limited |
Způsob přípravy antipsychotického 3-[2-[4-(6-fluor-1,2-benzizoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2,-a]pyrimidin-4-onu
|
US6264987B1
(en)
|
2000-05-19 |
2001-07-24 |
Alkermes Controlled Therapeutics Inc. Ii |
Method for preparing microparticles having a selected polymer molecular weight
|
US6495164B1
(en)
|
2000-05-25 |
2002-12-17 |
Alkermes Controlled Therapeutics, Inc. I |
Preparation of injectable suspensions having improved injectability
|
WO2002012200A1
(en)
*
|
2000-08-08 |
2002-02-14 |
Teva Pharmaceutical Industries Ltd. |
Preparation of risperidone
|
HUP0302874A2
(hu)
*
|
2000-08-14 |
2003-12-29 |
Teva Pharmaceutical Industries Ltd. |
Eljárás risperidon előállítására
|
EP1783118B1
(en)
*
|
2000-08-14 |
2008-07-16 |
Teva Pharmaceutical Industries Ltd. |
Preparation of risperidone
|
US6824822B2
(en)
|
2001-08-31 |
2004-11-30 |
Alkermes Controlled Therapeutics Inc. Ii |
Residual solvent extraction method and microparticles produced thereby
|
US20040023951A1
(en)
*
|
2001-06-18 |
2004-02-05 |
Bymaster Franklin Porter |
Combination therapy for treatment of psychoses
|
DE10129320A1
(de)
|
2001-06-19 |
2003-04-10 |
Norbert Mueller |
Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
|
US6730772B2
(en)
|
2001-06-22 |
2004-05-04 |
Venkatram P. Shastri |
Degradable polymers from derivatized ring-opened epoxides
|
JP2005504783A
(ja)
*
|
2001-08-31 |
2005-02-17 |
ノバルティス アクチエンゲゼルシャフト |
イロペリドン代謝産物の光学異性体
|
HU227118B1
(en)
*
|
2001-11-13 |
2010-07-28 |
Egis Gyogyszergyar Nyilvanosan |
Process for the preparation of 3-{2-[4-(6-fluoro-1,2-benzizoxazol-3-yl)-1-piperidinyl]-ethyl}-6,7,8,9-tetrahydro-2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one
|
WO2003054226A2
(en)
*
|
2001-12-10 |
2003-07-03 |
Novartis Ag |
Methods of treating psychosis and schizophrenia based on a polymorphism in the ctf gene
|
ES2197801B1
(es)
|
2002-03-05 |
2005-03-16 |
Ferrer Internacional,S.A |
Procedimiento de obtencion de la 3-(2-(4-(6-fluoro-benzo(d)isoxazol-3-il) piperidin-1-il)-etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido-(1,2-a ) pirimidin-4-ona.
|
WO2004009591A1
(en)
*
|
2002-07-22 |
2004-01-29 |
Aurobindo Pharma Ltd. |
A process for the preparation of antipsychotic risperidone
|
US20050232995A1
(en)
*
|
2002-07-29 |
2005-10-20 |
Yam Nyomi V |
Methods and dosage forms for controlled delivery of paliperidone and risperidone
|
US20060148826A1
(en)
*
|
2002-08-23 |
2006-07-06 |
Ashish Gogia |
Stable aqueous solutions of risperidone and methods for their preparation
|
WO2004020439A2
(en)
*
|
2002-08-30 |
2004-03-11 |
Sunil Sadanand Nadkarni |
Improved process for preparation of risperidone
|
KR20040025224A
(ko)
*
|
2002-09-18 |
2004-03-24 |
주식회사 대웅 |
2-(2-메틸-4-옥소-6,7,8,9-테트라하이드로-4H-피리도[1,2-a]피리미딘-3-일)아세트알데히드 및 그 제조방법
|
US6800663B2
(en)
*
|
2002-10-18 |
2004-10-05 |
Alkermes Controlled Therapeutics Inc. Ii, |
Crosslinked hydrogel copolymers
|
KR20040034996A
(ko)
*
|
2002-10-18 |
2004-04-29 |
한미약품 주식회사 |
리스페리돈의 개선된 제조방법
|
EP1560814A1
(en)
|
2002-11-13 |
2005-08-10 |
Synthon B.V. |
Process for making risperidone and intermediates therefor
|
DE10259382A1
(de)
*
|
2002-12-18 |
2004-07-01 |
Abbott Gmbh & Co. Kg |
3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-4-on-Derivate, ihre Herstellung und Verwendung
|
US7658998B2
(en)
*
|
2003-01-22 |
2010-02-09 |
Alkermes Controlled Therapeutics, Inc. |
Method of preparing sustained release microparticles
|
WO2004094414A1
(en)
*
|
2003-04-22 |
2004-11-04 |
Synthon B.V. |
Water soluble salts of risperidone
|
RU2005135454A
(ru)
*
|
2003-05-16 |
2006-06-27 |
Пфайзер Продактс Инк. (Us) |
Терапевтические комбинации атипичных нейролептиков с модуляторами гамк и/или противосудорожными препаратами
|
US20050036977A1
(en)
*
|
2003-08-11 |
2005-02-17 |
Dilip Gole |
Taste-masked resinate and preparation thereof
|
AU2004276092A1
(en)
*
|
2003-09-26 |
2005-04-07 |
Jubilant Organosys Ltd. |
Process for the preparation of risperidone
|
GB0322994D0
(en)
*
|
2003-10-01 |
2003-11-05 |
Novartis Ag |
Organic compounds
|
PT1675573E
(pt)
*
|
2003-10-23 |
2008-12-30 |
Otsuka Pharma Co Ltd |
Formulação de iripiprazole injectável estéril de libertação controlada e um processo para a sua preparação
|
GB0326148D0
(en)
|
2003-11-10 |
2003-12-17 |
Lilly Co Eli |
Morpholine derivatives
|
ATE473967T1
(de)
*
|
2003-11-26 |
2010-07-15 |
Pfizer Prod Inc |
Aminopyrazolderivate als gsk-3-inhibitoren
|
US20050233010A1
(en)
*
|
2004-04-19 |
2005-10-20 |
Satow Philip M |
Lithium combinations, and uses related thereto
|
WO2005107808A2
(en)
*
|
2004-05-11 |
2005-11-17 |
Pfizer Products Inc. |
Combination of atypical antipsychotics and 5-ht1b receptor antagonists
|
MY147767A
(en)
|
2004-06-16 |
2013-01-31 |
Janssen Pharmaceutica Nv |
Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
|
TW200612905A
(en)
*
|
2004-06-16 |
2006-05-01 |
Janssen Pharmaceutica Nv |
Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
|
US20060004199A1
(en)
*
|
2004-07-01 |
2006-01-05 |
Dr. Reddy's Laboratories Limited |
Process for the preparation of pure 3-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-1-piperidinyl]-ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one
|
TW200616608A
(en)
*
|
2004-07-09 |
2006-06-01 |
Forest Laboratories |
Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
|
AU2005277134A1
(en)
*
|
2004-08-24 |
2006-03-02 |
Janssen Pharmaceutica N.V. |
Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
|
US7744918B2
(en)
*
|
2004-11-22 |
2010-06-29 |
Hisamitsu Pharmaceutical Co., Inc. |
Drug-containing patch
|
WO2006101745A2
(en)
*
|
2005-03-18 |
2006-09-28 |
Abbott Laboratories |
Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions
|
BRPI0610028A2
(pt)
*
|
2005-04-22 |
2010-05-18 |
Wyeth Corp |
combinações terapêuticas para o tratamento ou a prevenção de distúrbios psicóticos
|
WO2006127184A1
(en)
*
|
2005-05-20 |
2006-11-30 |
Janssen Pharmaceutica N.V. |
Process for preparation of sulfamide derivatives
|
WO2006129160A2
(en)
*
|
2005-06-01 |
2006-12-07 |
Aurobindo Pharma Limited |
Stable aqueous oral solution of risperidone
|
EP2279727A3
(en)
*
|
2005-09-15 |
2011-10-05 |
Elan Pharma International Limited |
Nanoparticulate aripiprazole formulations
|
US20070134310A1
(en)
*
|
2005-09-23 |
2007-06-14 |
Nedberge Diane E |
Transdermal risperidone delivery system
|
US8852638B2
(en)
|
2005-09-30 |
2014-10-07 |
Durect Corporation |
Sustained release small molecule drug formulation
|
US8716231B2
(en)
|
2005-12-19 |
2014-05-06 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
|
US8691867B2
(en)
*
|
2005-12-19 |
2014-04-08 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
|
US8497298B2
(en)
*
|
2005-12-19 |
2013-07-30 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
|
US20070155823A1
(en)
*
|
2005-12-19 |
2007-07-05 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
|
AR058389A1
(es)
*
|
2005-12-19 |
2008-01-30 |
Janssen Pharmaceutica Nv |
Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
|
US20070155827A1
(en)
*
|
2005-12-19 |
2007-07-05 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
|
US8937096B2
(en)
|
2005-12-19 |
2015-01-20 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
|
US20070155824A1
(en)
*
|
2005-12-19 |
2007-07-05 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
|
US20070191474A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
|
US20070191460A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
|
GB0603087D0
(en)
*
|
2006-02-15 |
2006-03-29 |
Glaxo Group Ltd |
Novel use
|
US20070191450A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
|
US20070191451A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
|
JP4922657B2
(ja)
*
|
2006-05-09 |
2012-04-25 |
高田製薬株式会社 |
リスペリドン経口用液剤
|
AU2007253814A1
(en)
*
|
2006-05-19 |
2007-11-29 |
Janssen Pharmaceutica N.V. |
Co-therapy for the treatment of epilepsy
|
JP2009538331A
(ja)
*
|
2006-05-22 |
2009-11-05 |
ヴァンダ ファーマシューティカルズ インコーポレイテッド |
抑うつ障害のための治療
|
ATE523602T1
(de)
|
2006-06-12 |
2011-09-15 |
Hadasit Med Res Service |
Mit durch antipsychotika induzierten extrapyramidalen symptomen assoziierte rgs2- genotypen
|
US20080004260A1
(en)
*
|
2006-06-29 |
2008-01-03 |
Transcept Pharmaceuticals, Inc. |
Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
|
JP2009512627A
(ja)
*
|
2006-08-14 |
2009-03-26 |
テバ ファーマシューティカル インダストリーズ リミティド |
9−ヒドロキシリスペリドン(パリペリドン)の合成方法
|
WO2008047340A1
(en)
*
|
2006-10-19 |
2008-04-24 |
Mor Research Applications Ltd. |
Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders
|
CA2670116C
(en)
|
2006-11-22 |
2015-03-10 |
Seaside Therapeutics, Llc |
Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism
|
WO2008087557A2
(en)
*
|
2007-01-08 |
2008-07-24 |
Actavis Group Ptc Ehf |
An improved process for preparation of 9-hydroxy-3-(2-chloroethyl)- 2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one hydrochloride
|
CN101245065B
(zh)
*
|
2007-02-14 |
2010-05-19 |
江苏恩华药业股份有限公司 |
制备苯并异噁唑衍生物的方法及其中间体
|
JP4941977B2
(ja)
*
|
2007-04-11 |
2012-05-30 |
大蔵製薬株式会社 |
ベンズイソキサゾール誘導体の経口ゼリー状医薬組成物
|
CN101801415B
(zh)
*
|
2007-05-25 |
2015-09-23 |
Rb医药品有限公司 |
利培酮化合物的持续递送制剂
|
RU2483711C2
(ru)
*
|
2007-07-31 |
2013-06-10 |
Оцука Фармасьютикал Ко., Лтд. |
Способы получения суспензии арипипразола и лиофилизированного состава
|
WO2009056990A2
(en)
*
|
2007-08-21 |
2009-05-07 |
Actavis Group Ptc Ehf |
Paliperidone polymorphs
|
WO2009025859A1
(en)
*
|
2007-08-21 |
2009-02-26 |
Teva Pharmaceutical Industries Ltd. |
Paliperidone sustained release formulation
|
US7776866B2
(en)
*
|
2007-09-15 |
2010-08-17 |
Protia, Llc |
Deuterium-enriched risperidone
|
US7977480B2
(en)
|
2007-12-10 |
2011-07-12 |
Synthon Bv |
Synthesis of paliperidone
|
KR20100099292A
(ko)
*
|
2007-12-19 |
2010-09-10 |
얀센 파마슈티카 엔.브이. |
장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법
|
US20090247617A1
(en)
*
|
2008-03-26 |
2009-10-01 |
Abdel-Magid Ahmed F |
Process for the preparation of benzo-fused heteroaryl sulfamates
|
WO2009118655A2
(en)
*
|
2008-03-27 |
2009-10-01 |
Actavis Group Ptc Ehf |
Highly pure paliperidone or a pharmaceutically acceptable salt thereof substantially free of keto impurity
|
US20110034565A1
(en)
|
2008-04-18 |
2011-02-10 |
University College Dublin, National University Of Ireland, Dublin |
Psycho-pharmaceuticals
|
WO2010004578A2
(en)
|
2008-06-16 |
2010-01-14 |
Msn Laboratories Limited |
Novel and improved processes for the preparation of paliperidone
|
AU2009271362B2
(en)
|
2008-06-23 |
2014-03-13 |
Janssen Pharmaceutica Nv |
Crystalline form of (2s)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
|
WO2009156889A1
(en)
*
|
2008-06-25 |
2009-12-30 |
Pfizer Inc. |
Diaryl compounds and uses thereof
|
EP2138495A1
(en)
*
|
2008-06-26 |
2009-12-30 |
sanofi-aventis |
Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives
|
EP2138488A1
(en)
*
|
2008-06-26 |
2009-12-30 |
sanofi-aventis |
4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
|
EP2138492A1
(en)
*
|
2008-06-26 |
2009-12-30 |
Sanofi-Aventis |
Substituted pyrimidin-4-one derivatives
|
EP2138493A1
(en)
*
|
2008-06-26 |
2009-12-30 |
Sanofi-Aventis |
Substituted pyrimidone derivatives
|
EP2138494A1
(en)
*
|
2008-06-26 |
2009-12-30 |
Sanofi-Aventis |
Substituted alkyl pyrimidin-4-one derivatives
|
EP2138498A1
(en)
*
|
2008-06-26 |
2009-12-30 |
sanofi-aventis |
Substituted tricyclic derivatives against neurodegenerative diseases
|
EP2138485A1
(en)
*
|
2008-06-26 |
2009-12-30 |
sanofi-aventis |
Substituted N-Oxide pyrazine derivatives
|
EP2318405A2
(en)
|
2008-07-11 |
2011-05-11 |
Synthon B.V. |
Paliperidone ketone
|
US8815939B2
(en)
*
|
2008-07-22 |
2014-08-26 |
Janssen Pharmaceutica Nv |
Substituted sulfamide derivatives
|
EP2199293A1
(en)
|
2008-12-22 |
2010-06-23 |
Chemo Ibérica, S.A. |
One-step process for preparing paliperidone and its oxalate salt
|
US20100298397A1
(en)
*
|
2009-05-19 |
2010-11-25 |
Singh Nikhilesh N |
Method of treatment of obsessive compulsive disorder with ondansetron
|
WO2010136895A1
(en)
|
2009-05-28 |
2010-12-02 |
Actavis Group Ptc Ehf |
Solid state forms of paliperidone salts and process for the preparation thereof
|
US8252801B1
(en)
|
2009-06-03 |
2012-08-28 |
Abbott Laboratories |
Treatment of schizophrenia and related disorders
|
SI2275423T1
(sl)
|
2009-07-13 |
2012-06-29 |
Krka D.D., Novo Mesto |
Postopek za sintezo paliperidona
|
WO2011030224A2
(en)
|
2009-09-10 |
2011-03-17 |
Actavis Group Ptc Ehf |
Paliperidone or a pharmaceutically acceptable salt thereof substantially free of impurities
|
ES2647361T3
(es)
|
2010-01-07 |
2017-12-21 |
Alkermes Pharma Ireland Limited |
Profármacos de sales de amonio cuaternario
|
US9271939B2
(en)
|
2010-03-15 |
2016-03-01 |
Inventia Healthcare Private Limited |
Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
|
GB2481017B
(en)
|
2010-06-08 |
2015-01-07 |
Rb Pharmaceuticals Ltd |
Microparticle buprenorphine suspension
|
US9272044B2
(en)
|
2010-06-08 |
2016-03-01 |
Indivior Uk Limited |
Injectable flowable composition buprenorphine
|
WO2012012147A2
(en)
|
2010-06-30 |
2012-01-26 |
Victoria Link Ltd |
Methods and compositions for treatment of multiple sclerosis
|
SI2608670T1
(sl)
|
2010-08-23 |
2019-04-30 |
Alkermes Pharma Ireland Limited |
Postopki za zdravljenje pridobivanja teže, ki je posledica uporabe antipsihotičnih zdravil
|
WO2012035554A1
(en)
|
2010-09-14 |
2012-03-22 |
Megafine Pharma (P) Ltd. |
An improved process for the preparation of highly pure paliperidone
|
WO2012068161A1
(en)
|
2010-11-15 |
2012-05-24 |
Agenebio, Inc. |
Pyridazine derivatives, compositions and methods for treating cognitive impairment
|
PL2702060T3
(pl)
|
2011-04-26 |
2016-06-30 |
Torrent Pharmaceuticals Ltd |
Kwasowe addycyjne sole risperidonu i ich kompozycje farmaceutyczne
|
WO2013095314A1
(en)
|
2011-12-19 |
2013-06-27 |
Mahmut Bilgic |
Pharmaceutical formulations comprising risperidone
|
WO2013100876A1
(en)
|
2011-12-27 |
2013-07-04 |
Mahmut Bilgic |
Risperidone formulations
|
AU2013305938B2
(en)
|
2012-08-21 |
2017-08-17 |
Saladax Biomedical Inc. |
Antibodies to paliperidone haptens and use thereof
|
PL2888284T3
(pl)
*
|
2012-08-21 |
2023-02-27 |
Janssen Pharmaceutica Nv |
Przeciwciała przeciwko haptenom rysperydonu i ich zastosowanie
|
CA2882490A1
(en)
|
2012-08-21 |
2014-02-27 |
Ortho-Clinical Diagnostics, Inc. |
Antibodies to paliperidone and use thereof
|
PT2888593T
(pt)
|
2012-08-21 |
2018-12-12 |
Janssen Pharmaceutica Nv |
Anticorpos contra risperidona e utilizações dos mesmos
|
JP6131500B2
(ja)
*
|
2012-08-21 |
2017-05-24 |
ヤンセン ファーマシューティカ エヌ.ベー. |
リスペリドン及びパリペリドンのハプテン
|
WO2014052837A1
(en)
*
|
2012-09-28 |
2014-04-03 |
Delpor, Inc. |
Device and methods for sustained release of antipsychotic medications
|
JP6440625B2
(ja)
|
2012-11-14 |
2018-12-19 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
精神分裂病を処置するための方法および組成物
|
EP3083569B1
(en)
|
2013-12-20 |
2022-01-26 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
GB201404139D0
(en)
|
2014-03-10 |
2014-04-23 |
Rb Pharmaceuticals Ltd |
Sustained release buprenorphine solution formulations
|
CA3015557C
(en)
|
2014-11-07 |
2019-07-16 |
Indivior Uk Limited |
The use of sustained-release buprenorphine formulations for the treatment of pain or opioid use disorders
|
CN108026107B
(zh)
|
2015-06-19 |
2021-07-30 |
艾吉因生物股份有限公司 |
用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
|
CN108431040B
(zh)
|
2015-12-17 |
2022-07-26 |
詹森药业有限公司 |
利培酮的抗体及其用途
|
BR112019012821A2
(pt)
|
2016-12-19 |
2019-11-26 |
Agenebio Inc |
derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
|
US20180170941A1
(en)
|
2016-12-19 |
2018-06-21 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
US10646484B2
(en)
|
2017-06-16 |
2020-05-12 |
Indivior Uk Limited |
Methods to treat opioid use disorder
|
CA3104478A1
(en)
|
2018-06-19 |
2019-12-26 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
WO2024039886A1
(en)
|
2022-08-19 |
2024-02-22 |
Agenebio, Inc. |
Benzazepine derivatives, compositions, and methods for treating cognitive impairment
|